DrSuparna Krishnaiengar
ASO PRG DIR & CLIN ASO PROF
JX-NEUROLOGY-JACKSONVILLE
- ASO PRG DIR & CLIN ASO PROFJX-NEUROLOGY-JACKSONVILLE
GRANTS
- GRANT“A Phase 2, Global, Multicenter, Long-term Safety Study Designed to Assess the Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy”Biohaven Pharmaceuticals2 Jul 2024 - 2 Jul 2029
- GRANTA Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset EpilepsyBiohaven Pharmaceuticals21 Feb 2024 - 21 Feb 2029
- GRANTAN OPEN-LABEL, MULTICENTER, OUTPATIENT EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF STACCATO ALPRAZOLAM IN STUDY PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH STEREOTYPICAL PROLONGED SEIZURESUcb Biopharma Srl20 Apr 2022 - 20 Apr 2027
- GRANTA DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, OUTPATIENT, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF STACCATO ALPRAZOLAM IN STUDY PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH STEREOTYPICAL PROLONGED SEIZURESUcb Biopharma Srl17 Apr 2022 - 17 Apr 2027
- GRANTAN OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PADSEVONIL AS ADJUNCTIVE TREATMENT OF FOCAL ONSET SEIZURES IN ADULT SUBJECTS WITH DRUG-RESISTANT EPILEPSYUcb Biosciences4 May 2020 - 21 Feb 2023
- GRANTA Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset EpilepsyXenon Pharmaceuticals12 Mar 2020 - 30 Nov 2023
- GRANTA Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects with Drug-Resistant EpilepsyUcb Biosciences12 Apr 2019 - 21 Feb 2023